anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a burn treatment patch. The burn treatment patch comprises a medical pressure-sensitive transparent adhesive patch, a cotton cloth and medical gauze. The medical pressure-sensitive transparent adhesive patch is provided with a large hole in the center, six layers of structures orderly coat the lower surface of the large hole and the six layers of the structures orderly comprise a cotton cloth layer, a first thin absorbent cotton layer, a first adsorbent layer, a second absorbent cotton layer, a second adsorbent layer and medical gauze from top to bottom. The lower surface of the medical pressure-sensitive transparent adhesive patch is a bonding side. The first adsorbent layer and the second adsorbent layer comprise wood carbon powder prepared from branches and trunk of Phellodendron chinense. The burn treatment patch can be used for treating burn and scald. The burn treatment patch has effects of clearing away heat and drying dampness, and relieving swelling and pain, has a low cost, can be prepared easily and is convenient for use. Multitime clinical experiments prove that the burn treatment patch can reduce exudation in burn and scald positions, keep dryness and promote heal. The burn treatment patch is especially suitable for treatment on burn and scald degree II.
Ferroptosis induces significant changes in mitochondrial morphology, including membrane condensation, volume reduction, cristae alteration, and outer membrane rupture, affecting mitochondrial function and cellular fate. Recent reports have described the intrinsic cellular iron metabolism and its intricate connection to ferroptosis, a significant kind of cell death characterized by iron dependence and oxidative stress regulation. Furthermore, updated molecular insights have elucidated the significance of mitochondria in ferroptosis and its implications in various cancers. In the context of cancer therapy, understanding the dual role of anastasis and ferroptosis in chemoresistance is crucial. Targeting the molecular pathways involved in anastasis may enhance the efficacy of ferroptosis inducers, providing a synergistic approach to overcome chemoresistance. Research into how DNA damage response (DDR) proteins, metabolic changes, and redox states interact during anastasis and ferroptosis can offer new insights into designing combinatorial therapeutic regimens against several cancers associated with stemness. These treatments could potentially inhibit anastasis while simultaneously inducing ferroptosis, thereby reducing the likelihood of cancer cells evading death and developing resistance to chemotherapy. The objective of this study is to explore the intricate interplay between anastasis, ferroptosis, EMT and chemoresistance, and immunotherapeutics to better understand their collective impact on cancer therapy outcomes. We searched public research databases including google scholar, PubMed, relemed, and the national library of medicine related to this topic. In this review, we discussed the interplay between the tricarboxylic acid cycle and glycolysis implicated in modulating ferroptosis, adding complexity to its regulatory mechanisms. Additionally, the regulatory role of reactive oxygen species (ROS) and the electron transport chain (ETC) in ferroptosis has garnered significant attention. Lipid metabolism, particularly involving GPX4 and System Xc- plays a significant role in both the progression of ferroptosis and cancer. There is a need to investigate the intricate interplay between anastasis, ferroptosis, and chemoresistance to better understand cancer therapy clinical outcomes. Integrating anastasis, and ferroptosis into strategies targeting chemoresistance and exploring its potential synergy with immunotherapy represent promising avenues for advancing chemoresistant cancer treatment. Understanding the intricate interplay among mitochondria, anastasis, ROS, and ferroptosis is vital in oncology, potentially revolutionizing personalized cancer treatment and drug development.
Adenosine infusion will be compared to Regadenoson for efficacy and safety/side effects. Arterial blood pressure, coronary pressure, heart rate, oxygen saturation and coronary flow, FFR, and coronary flow velocity will be assessed. Safety will be assessed by monitoring for any side effects such as chest pain, headache, flushing, nausea, or arrhythmias. Adenosine infusion will be administered at 140 mcg/kg for 2 minutes and once mean coronary flow velocity returns to within 15% of pre-dose value, Regadenoson IV bolus 0.4 mg/5 ml will be administered followed by a 5 cc normal saline flush.
Fluticasone propionate lotion may cause local adverse reactions, including skin atrophy [see Adverse Reactions (6.1, 6.2)]. The risk is greater with use under occlusion and with higher potency products.

Fluticasone propionate lotion contains the excipient imidurea which releases formaldehyde as a breakdown product. Formaldehyde may cause allergic sensitization or irritation upon contact with the skin. Avoid using fluticasone propionate lotion in individuals with hypersensitivity to formaldehyde as it may prevent healing or worsen dermatitis.

If irritation develops, discontinue fluticasone propionate lotion and institute appropriate therapy.

Allergic Contact Dermatitis

Allergic contact dermatitis with corticosteroids is usually diagnosed by observing a failure to heal rather than noticing a clinical exacerbation. Such an observation can be corroborated with appropriate diagnostic patch testing. Discontinue fluticasone propionate lotion if appropriate.
The goal of the CLINIC project is to develop a new approach to diagnose the causes of LiD in 6 to 14-year-old children with normal peripheral hearing. A multicentric, interventional study focuses on the longitudinal evaluation of children with various DDs: SLI, LD, ADHD, and ASS. These children are tested at different sites for three years consecutively with a multidisciplinary behavioral assessment app (CLINIC) that will allow assessing a broad range of skills (auditory abilities, speech processing skills, language abilities, neurocognitive abilities). Profiles of children with LiD will be constructed from the ECLiPS (Evaluation of Children's Listening and Processing Skills; a validated parent report questionnaire) and from the behavioral measures obtained with the CLINIC app, both at a population level and in specialized centers treating children with recognized DD. This will be done in a longitudinal design (3 years) with the same children, to determine age effects and to capture potential changes in the profiles of children with time. Results will be compared with performance of TD children, to determine cut-off criteria for establishing a diagnosis. Comparison of the ECLiPS and the behavioral measures will indicate whether the ECLiPS can be used as a screening measure in the future to help identify children in need of support (and to pinpoint in which domains the support needs to be prioritized).
Applied Suicide Intervention Skills Training is a 2-day, 14 hour intensive, interactive and practice-dominated course aimed at enabling people to recognize risk and learn how to intervene immediately to prevent suicide. The course, facilitated by 2 trained facilitators, allows for a maximum enrollment of 30 participants.
Patients receive oral everolimus once daily on days 1-28, leucovorin calcium IV followed by fluorouracil IV continuously over 46 hours beginning on day 1, and oxaliplatin IV over 2-4 hours on day 1. Some patients may also receive panitumumab IV over 30-90 minutes on day 1. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
The invention relates to a preparation method for a medicinal preparation, and particularly relates to a preparation method for chitosan drug-carrying microspheres by an ionic cross-linking method. Chitosan solid is weighed and dissolved in an acetic acid solution, and impurities in the chitosan are removed by suction filtration through a circulating water vacuum pump. A NaOH solution is added dropwise into the chitosan acetic acid solution. Under conditions that the mole ratio of positive charges to negative charges is 20:1-60:1, the cross-linking time is 5-25 min and the rotate speed is 300-700 rpm, the parameters are set up in a microwave reactor and a sodium pyrophosphate solution is added into the prepared chitosan acetic acid solution, and a chitosan microsphere solution is prepared. After the reaction is finished, the prepared chitosan microsphere solution is subjected to steps of centrifuging by using an automatic low-speed table-type centrifuge, removing supernatant liquid, washing with purified water, and finally freeze-drying products to obtain chitosan blank microspheres. The chitosan microspheres can be used for preparing lung-targeted medicament carriers. The chitosan microspheres are environmental friendly and non-toxic. The chitosan microspheres have a simple preparation technology and a low cost.
OBJECTIVES: Synthetic data may proxy clinical data. At the absence of direct clinical data, this study aimed to compare Irinotecan and Ifosfamide (II) with Topotecan in synthetic, recurrent small cell lung cancer (SCLC) patients within a simulated clinical trial.
MATERIALS AND METHODS: Two simulation stages were conducted. Initially, 200 recurrent SCLC cases were simulated to replicate a previous phase 3 trial, testing the utility of Cox proportional hazards model and simulation methodology together, where patients were randomized to receive Cyclophosphamide, Adriamycin, Vincristine (CAV) or Topotecan. In the second stage, 600 recurrent SCLC patients were simulated and randomized to compare Topotecan versus II in terms of overall survival (OAS), using Reinforcement Learning (RL) and Cox proportional hazards model.
RESULTS: CAV versus Topotecan comparison showed no statistical difference in overall survival (hazard ratio (HR): 0.89, 95% CI: 0.67-1.18, P = 0.418), aligning with the original clinical trial. For the Topotecan versus II comparison, the RL framework significantly favored the II arm (mean reward points: 193.43 versus - 251.82, permutation P < 0.0001). Likewise, II arm exhibited superior median OAS compared to Topotecan arm (11.12 versus 6.30 months). HR was 0.44 (95% CI: 0.38-0.52) with P < 0.0001, in favor of II.
CONCLUSION: Artificial trial results for CAV versus Topotecan matched the original trial, confirming indifference of OAS. Additionally, II yielded superior overall survival compared to Topotecan in recurrent SCLC patients. These demonstrate the potential of RL and simulation in conjunction with Cox modelling for similar studies. However, definitive conclusions necessitate a randomized clinical trial between II and Topotecan in this patient cohort.
Participants had two brain positron emission tomography (PET) scan visits. In one visit, participants had a baseline \[11C\]PS13 scan followed by a second \[11C\]PS13 scan after blockade with ketoprofen 75 mg orally. In another visit, participants had baseline \[11C\]MC1 scan followed by a second scan with \[11C\]MC1 after blockade by a dose of celecoxib 600 mg orally. Participants receive injection of up to 20 millicurie (mCi) of \[11C\]PS13 or \[11C\]MC1 during each scan.
We present a case of ocular injuries post bungee jumping in Nepal. A 26 year old female presented to our clinic with bilateral Sub Conjunctival Hemorrhage (SCH) after bungee jumping. Her best corrected visual acuity was 20/20 in both eyes. No other intraocular hemorrhage was revealed in her dilated ocular examination. Conservative treatments with artificial tears were given to her and follow up visit after one week was advised. The SCH was resolved after a treatment of one week. Her visual acuity remained stable and no other ocular complications were found. To conclude, bungee jumping can be the cause of several ocular injuries. Further studies are required to identify the causes and potential risk factors. Keywords: Bungee jumping, ocular injury; sub conjunctival haemorrhage.
Techniques of regional analgesia such as epidural analgesia may favorably influence metastasis development following cancer surgery compared to analgesia based on strong opioids such as morphine or piritramide. These beneficial effects, if present, are probably attributable to less immunosuppression of antimetastatic immune defenses.

The aim of this study is to identify techniques of perioperative analgesia with the potential to prevent metastasis development in patients undergoing open radical colon cancer surgery. In the early postoperative period, a relationship between metastasis development and the number of circulating cancer cells representing minimal residual disease has been shown. Therefore, effects of epidural, morphine-based and piritramide-based analgesia on the number of circulating cancer cells will be compared at several time points during the peroperative and early postoperative periods. The number of circulating cancer cells will be assessed in peripheral venous blood samples using real-time polymerase chain reaction. Perioperative care will be standardized and patients will be followed by clinical observation, laboratory analyses and monitoring instrumentation daily during their hospital stay.
The investigators will use a parallel-group, double-blinded, randomized, sham-stimulation-controlled design. Forty LBDs patients will be randomized into two parallel groups, n = 20 subjects in each arm. For the active group, the investigators will use the stimulation protocol with the anode over the left IFG (cathode over the right supraorbital area, 2mA, 20 minutes). Participants will undergo a baseline assessment (A0, as described in arm 1); 10 stimulation sessions (in a two-week period); a follow-up assessment immediately after tDCS treatment (A1), and follow-up assessments 8 weeks (A2) after the baseline assessment. Each assessment will consist of a brief neuropsychological assessment, speech and writing recording and MRI scanning.
Caregiver stakeholders were bereaved family members of a patient who had died from solid tumor cancer in the past year. Stakeholders reviewed an initial version of the Oncolo-GIST manual to provide feedback and refine the manual for Phase 2.
The SH and H groups' patients were instructed to visit for routine controls without receiving any periodontal treatment. However, after the GCF sampling, patients in the SP and P groups received Non-surgical periodontal treatment(NSPT) included detailed oral hygiene instruction and reinforcement in conjunction with scaling and root planning as a full mouth debridement protocol in a single session They were instructed to refrain from using any chemicals, including mouthwash, to remove plaque.

The periodontitis patients received a follow-up call on the 15th and 30th days following treatment. The GCF sampling procedure was first repeated on the teeth from which a previous GCF sample had been taken. Then, values for the clinical examination parameters (PI, GI, BOP, PD, and CAL) were once again measured and recorded. Daily plaque care efficacy or deficiency was checked and/or reinforced at every recall. All these procedures were performed by a single investigator.
Patients in the experimental group will have a 30 cc transcervical Foley balloon placed in the outpatient setting approximately 12-18 hours prior to their labor induction. Once admitted, they will undergo inpatient labor induction as per usual protocols.
Systems, methods, and apparatus may be provided for providing a medical product assistant to identify a medical product. A first message may be received from a user interface. The first message may indicate a request from a user to identify an object. A portion of the object may be determined using the device's camera. A confidence level associated with a medical product may be generated. The generated confidence level may indicate confidence that the object is the medical product. The generated confidence level may be based on the portion of the object and a product detection model. The product detection model may have been trained using synthetic product detection data that may comprise at least a computer-generated image of the medical product. The object may be identified as the medical product when the confidence level satisfies a threshold.
PURPOSE: A pharmaceutical composition containing cyclosporin, as well as a hydrophilic phase, a lipophilic phase and a surfactant is provided. The composition is a preconcentrate of O/W microemulsion and has high bioavailability and its bioavailability has low change rate as compared to conventional cyclosporin preparation. It is hardly affected by a substance such as a bile acid salt as compared to conventional herbal preparation. CONSTITUTION: The pharmaceutical composition includes: 5 to 25% by weight of cyclosporin A as an active component; (1) 15 to 85% by weight of a hydrophilic component(except for tetrahydrofurfuryl di-ether or partial-ether, lower alkanol, 1,2-propylene glycol of low molecular mono-oxy alkanediol or poly-oxy alkanediol) such as Transcutol; (2) 2 to 40% by weight of a lipophilic component such as medium chain fatty acid triglyceride; and (3) 15 to 85% by weight of a surfactant, based on the total weight of (1)+(2)+(3). The composition contains C1-5 alkyl di- or partial-ether of pharmaceutically acceptable low molecular weight mono- or poly-oxy alkanediol. The composition provides an O/W microemulsion having an average particle size of 2,000 angstroms.
MI Paste® which is Casein phosphopeptide-Amorphous calcium phosphate fluoride (CPP-ACPF) additional contains fluoride in addition to CPP-ACP. The level of fluoride is 900ppm which approximates that in adult strength toothpastes. Recent studies have investigated the remineralization potential of CPP-ACP combined with fluoride and have found a synergistic effect when these are administered together, which is the composition in MI paste. One tube of the MI Paste will be prescribed to the patient. Patient will be instructed to apply the product using finger every night after brushing and flossing. This is continued till the prescribed product is finished. This is approximately calculated to be about 8 to 12 weeks.Patient is instructed to leave the paste for about 3 minutes and then rinse. This is based on the manufacturer's instructions.
The invention discloses a dietary intake suggestion system, a dietary intake suggestion method and a diet ordering system. The dietary intake suggestion system includes a server and an electronic device. The server provides a dietary reduction suggestion information based on a user's dietary habits information, and the server transmits a dietary reduced suggestion information to the electronic device. The diet reduced suggestion information includes a suggested diet type and a suggested diet amount. The suggested diet type is the same as the user's customary diet type. A ratio of the diet suggested amount and the user’s customary diet amount is less than or equal to a first predetermined ratio.
OBJECTIVE: This study aimed to compare the risks of adverse perinatal outcomes by body mass index (BMI) categories in healthy pregnant individuals delivered by term elective repeat cesarean (ERCD) to describe an optimal timing of delivery in otherwise healthy patients at the highest-risk BMI threshold.
STUDY DESIGN: A secondary analysis of a prospective cohort of pregnant individuals undergoing ERCD at 19 centers in the Maternal-Fetal Medicine Units Network from 1999 to 2002. Nonanomalous singletons undergoing prelabor ERCD at term were included. The primary outcome was composite neonatal morbidity; secondary outcomes included composite maternal morbidity and individual components of the composites. Patients were stratified by BMI classes and to identify a BMI threshold for which morbidity was the highest. Outcomes were then examined by completed week's gestation, between BMI classes. Multivariable logistic regression was used to calculate adjusted odds ratios (aOR) and 95% confidence intervals (CI).
RESULTS: A total of 12,755 patients were included in analysis. Patient's with BMI ≥ 40 had the highest rates of newborn sepsis, neonatal intensive care unit admissions, and wound complications. While a weight-related response was observed between BMI class and neonatal composite morbidity (p < 0.001), only those with BMI ≥ 40 had significantly higher odds of composite neonatal morbidity (aOR: 1.4, 95% CI: 1.0-1.8). In analyses of patients with BMI ≥ 40 (n = 1,848), there was no difference in the incidence of composite neonatal or maternal morbidity across weeks' gestation at delivery; however, as gestational age approached 39 to 40 weeks, rates of adverse neonatal outcomes decreased, only to increase again at 41 weeks' gestation. Of note, the odds of the primary neonatal composite were the highest at 38 weeks compared with 39 weeks (aOR: 1.5, 95% CI: 1.1-2.0).
CONCLUSION: Neonatal morbidity is significantly higher in pregnant individuals with BMI ≥40 delivering by ERCD. Despite this increased perinatal morbidity, delivery prior to 39 and after 41 weeks in these patients is associated with increased neonatal risks.
KEY POINTS: · Obese patients without additional comorbidities have higher rates of neonatal morbidity.. · Patients with BMI ≥ 40 carry the highest odds of poor perinatal outcomes.. · Earlier timing of delivery does not appear to reduce this risk..
All patients were treated with radial extracorporeal shock waves using the Swiss Dolorclast (Electro Medical Systems S.A., Nyon, Switzerland) and the Power+ handpiece with the 36-mm applicator. Patients were treated unilaterally with two weekly treatments for four weeks on a randomly selected leg (left or right), totaling eight treatments on the selected side. After the application of coupling gel, treatment was performed at 3.5 to 4 bar, with 15,000 impulses per session, and applied at 15 Hz. Impulses were applied homogeneously over the posterior thigh and buttock area. One patient was treated on both legs, with each leg considered an independent treatment.
The invention relates to a construction method and application of an anthracycline antitumor drug nanometer compound based on a DNA biomaterial, and belongs to the technical field of medicines. The nanometer compound is composed of ds M13mp18 RF I DNA, an anthracycline antitumor drug and a cationic polymer. The molar ratio scope of DNA to the anthracycline antitumor drug in the nanometer compound is 1:3200 to 1:130000, the N/P ratio scope of RLT polypeptide, cetyl trimethyl ammonium bromide and DNA is 0.5:1 to 10:1, and the N/P ratio scope of polyethyleneimine to DNA is 1:2000 to 20:1. The nanometer compound has the average particle size less than 800 nm. The nanometer compound has slow release and targeting effects, and is capable of reducing toxic and side effects of the anthracycline antitumor drug and improving the antitumor effect on tumor cells. The preparation technology is simple, and the nanometer compound is good in stability, high in drug loading capacity, high in yield, low in cost and suitable for industrialized production.